POPULARITY
In a conversation with CancerNetwork® during Pancreatic Cancer Awareness Month, Tanios S. Bekaii-Saab, MD, spoke about various developments in the pancreatic cancer treatment field. Throughout the discussion, Bekaii-Saab weighed the benefits of currently available chemotherapeutic regimens for patients with metastatic disease, discussed research on the potential for precision medicine in those with KRAS wildtype pancreatic ductal adenocarcinoma (PDAC), and detailed ongoing initiatives to improve outcomes among those with RAS mutations and other targetable genomic alterations. Bekaii-Saab is the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research, chair and consultant in the Division of Hematology and Medical Oncology at Mayo Clinic in Arizona, and co-leader of Advanced Clinical and Translational Science at Mayo Clinic Cancer Center. Given the prevalence of RAS mutations and other alterations in patients with pancreatic cancer, Bekaii-Saab especially emphasized the use of genomic analysis to inform personalized treatment decision-making in the field. Screening patients to detect aberrations such as microsatellite instability-high tumors, BRAF 600E mutations, KRAS G12C mutations, and NRG1 fusions can open the door for the development and use of targeted agents, which may consequently improve patient outcomes. Looking ahead, Bekaii-Saab noted the need to adapt the therapies that have shown activity in the later stages of the disease to earlier treatment settings. Although “great work” has been achieved with chemotherapy and surgical techniques, he highlighted the importance of bringing targeted agents to earlier lines of therapy to further increase the likelihood of positive outcomes for patients. “I have never been more optimistic. I'm always the eternal optimist, but I'm even more optimistic today that we're going to move the needle for our patients with pancreatic cancer and continue to enhance that likelihood of living longer, having a better quality of life, or even increasing the level of a cure for this cancer,” Bekaii-Sabb stated. “Certainly, the future looks bright. We're chipping away, one drug at a time. We can now remove that whole concept of nihilism in pancreatic cancer and look quite optimistically on the future.”
This week's podcast from VJOncology explores key advancements in the treatment of PD-1 refractory melanoma. Hear from leading experts, Alison... The post Novel therapeutics in PD-1 refractory melanoma appeared first on VJOncology.
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Drs. Drs. Anne Knisely and Nitecki Wilke to discuss Racial and Sociodemographic Disparities with Novel Therapeutics. Dr. Knisely is a 3rd year gynecologic oncology fellow at MD Anderson Cancer Center. She is originally from the New York City area and completed her residency training in Ob/Gyn at Columbia University in 2022 where Dr. Jason Wright served as her primary research mentor. Her current research focuses on early phase clinical trials, minimal residual disease in ovarian cancer, and sociodemographic factors that affect oncologic treatment and outcomes. She is a current SGO/GOG-F BRIDGES Research Scholar. In her free time, she mostly chases around her two toddlers, Zoe (3.5) and Isaiah (2). Dr. Nitecki Wilke is a gynecologic oncologist and assistant professor at the department of gynecologic oncology and reproductive medicine at the University of Texas MD Anderson Cancer Center. Highlights: Of the 6242 patients who met inclusion criteria and were included in the final cohort, 4.4% received a PARP inhibitor, 34% received bevacizumab, and 6% received both. On multivariable analysis, non-Hispanic Black patients were 23% less likely than non-Hispanic white patients to receive either targeted therapy Most patients in the study were treated in the recurrent setting; we suspect that the potential barriers to guideline-concordant prescription of these therapeutics would persist in the upfront treatment setting, but future studies are required to validate this. A key area of focus to reduce disparities in access to targeted therapies should be ensuring adequate reimbursement for genetic/ biomarker testing as well as brainstorming creative solutions to expand access to genetic counseling, including the use of mainstreaming. Use of the SEER-Medicare database specifically reduces external validity of this study, but the results are nonetheless hypothesis generating and should spark conversation regarding potential inequitable receipt of PARP inhibitors and bevacizumab in advanced ovarian cancer
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Christian Récher, MD, PhD - Practical Considerations for FLT3 Inhibitors in Acute Myeloid Leukaemia: Optimising Our First-Line Approaches With Current and Novel Therapeutics
Dr. Lin Tian is a Scientific Director at the Max Planck Florida Institute for Neuroscience and Clinical Professor at the University of California, Davis. The main goal of Lin's lab is to develop, leverage, and also share novel optical and molecular tools that can help us to characterize neural signaling and find new treatment targets for neuropsychiatric disorders. In addition to her scientific and leadership roles, Lin is a mom, wife, and daughter. She often spends her free time with her family, driving her two sons to different activities, cheering for them at their swim meets and baseball games, and helping them with homework. Lin also enjoys walking her dog and doing things around the house. She earned her B.S. in Neuroscience from the University of Science and Technology of China and her Ph.D. in Biochemistry, Molecular, and Cellular Biology from Northwestern University. She then completed postdoctoral training at Howard Hughes Medical Institute's Janelia Research Campus. Lin remained at HHMI as a Research Specialist before joining the faculty at the University of California, Davis School of Medicine in 2012. She began her current position at Max Planck in 2023. Lin has received multiple awards and honors, including an NIH New Innovator Award, the W.M. Keck Foundation Award, the Human Frontier Science Program Young Investigator Award, and she has been named a Rita Allen Scholar and Hartwell Scholar. In our interview, she shares more about her life and science.
Drs. Lillian Siu and Melvin Chua discuss scientific innovations, disruptive technologies, and novel ways to practice oncology that were featured at the 2023 ASCO Breakthrough meeting in Yokohama, Japan, including CRISPR and gene editing, CAR T-cell and adoptive cell therapies, as well as emerging AI applications that are poised to revolutionize cancer care. TRANSCRIPT Dr. Melvin Chua: Hello, I'm Dr. Melvin Chua, your guest host of the ASCO Daily News Podcast today. I'm a radiation oncologist and I currently practice in the Division of Radiation Oncology at the National Cancer Center in Singapore. I also served as the chair-elect of the ASCO Breakthrough Program Committee, and, on today's episode, we'll be discussing key takeaways from this year's Breakthrough meeting. The global meeting in Yokohama, Japan, brought together world-renowned experts, clinicians, med-tech, pioneers, and novel drug developers to discuss scientific innovations and disruptive technologies that are transforming cancer care today. I'm joined by Dr. Lillian Siu, the chair of the Breakthrough Program Committee. Dr. Siu is a senior medical oncologist at the Princess Margaret Cancer Centre and a professor of medicine at the University of Toronto. You'll find our full disclosures in the transcript of this episode, and disclosures of all guests on the podcast are available at asco.org/DNpod. Lillian, it's great to be speaking with you today. Dr. Lillian Siu: Thanks, Dr. Chua. I'm happy to be here. Dr. Melvin Chua: We were just at ASCO Breakthrough, and it showcased some incredible scientific innovations, and really showed us how technology innovations in precision oncology, biotech, and artificial intelligence are transforming cancer care. What are your thoughts? Dr. Lillian Siu: Yeah, it was a really exciting meeting, Melvin. The theme of this year's Breakthrough meeting was “Shining a Light on Advances in Cancer Care.” And our Opening Session featured an illuminating keynote address by the renowned thought leader and tech trailblazer, Dr. Hiroshi or “Mickey” Mikitani, the founder and CEO of Rakuten and Rakuten Medical. In his address that was titled, “Innovative Technology and Oncology,” he spoke so passionately about innovation and really seeing around the corner to predict what is coming and taking risks. And I think that's what medicine is about, not just what we have in front of us, but to predict and forecast what's coming. I totally was inspired by his address, and I think a lot of the audience felt the same way. He also spoke to us a bit about his company's development in photoimmunotherapy using novel technology and light therapy in head and neck cancer. And I think that's also an area of new technology that we should watch in the next few years. Dr. Melvin Chua: I totally agree with you, Lillian. And one of the quotes that he spoke about really spoke to my heart. He spoke about the 2 choices: whether to do or not to do and not to do is not an option. So, I think that was a very compelling message to a lot of our audience at the meeting. So, on this same note, innovation is a driving force in oncology, and we saw countless examples of this throughout the Breakthrough meeting. Were there any sessions that really stood out for you? Dr. Lillian Siu: There were so many exciting sessions. First of all, there is the “Drugging the Undruggable” session. This is a really important session because in the past we felt that certain cancer targets such as KRAS, MYC, etc., are not druggable. KRAS G12C is the poster child in this area. So, during this session we heard about many ways that we are now looking to target these so-called undruggable molecules in the cancer cell. And we talked about molecular glues, we talked about degraders, and really novel ways that are not yet reaching the clinic, called “cyclic peptides” were discussed by one of the speakers. The other session that is very interesting also is CRISPR and gene editing. Obviously, we all know a little bit about gene editing, really trying to change or knock in some genes that are important perhaps to change the function. And one of the sessions talked about trail targeted induced mesenchymal stem cells, and perhaps this is a way to, again, deliver novel therapies and novel treatments to our patients. There were many examples of how CRISPR and gene editing can be ultimately going to the clinic to benefit our patients in terms of therapeutics. I want to highlight another session, which is the CAR T-cell and Adoptive Cell Therapies. I think everybody knows about CAR T-cells, but in this session we talk about non CAR T-cells or newer things such as off the shelf NK cells, Natural Killer cells from cord blood. So, this way it is allogeneics, in other words, we don't have to rely on only a patient's donation of their samples, but actually get it from off the shelf from other donors. There are other ways to really use human induced pluripotent stem cells that we can armor them by transgenes and also CRISPR out any unwanted genes, for example, to enhance an effective function of T-cells. So many, many exciting ways to bring these cell therapies to the patients. And last but not least, I want to highlight Dr. Chris Abbosh, who is one of our keynote speakers, talking about molecular and minimal residual disease and early cancer detection using circulating tumor DNA or liquid biopsy. He talked passionately about the TRACERx study, which he is instrumental in terms of leading together with Charlie Swanson in the UK. This is a study that really has uncovered a lot of science about cancer heterogeneity. And in that study, he also studied circulating tumor DNA and really shed a lot of light about clonal and subclonal dynamics over time that changes. Dr. Melvin Chua: And just to touch on that point about innovation and how that translates to cancer care, I think it was great that we had those case-based applications in lung cancer, in breast cancer, and the virus-associated cancers. And I like how the speakers were able to bring in the Ying and the Yang, bring the West and the Eastern perspectives in these interactive sessions. I particularly enjoyed all of them. But the session on the lung case discussion where we know that there were this EGFR mutant lung cancers that are prevalent in this part of the world in Asia. I thought the interaction between the speakers was fantastic. On the same note about therapies and we heard about novel therapeutics at this meeting as well. I wonder what your thoughts are about some of the sessions, and do you think some of these technologies were able to be brought into practice? And your thoughts on the novel therapeutic session that happened at Breakthrough, do you think this will actually impact clinical care? Dr. Lillian Siu: Oh, for sure, Melvin. The 5 areas that were covered during the Novel Therapeutics session are really drugs already in the clinic. And for example, the first one was about antibody drug conjugates. We know there are now at least 12 antibody drug conjugates already approved by the FDA and many more likely to be approved in the near future. And the session really talked about what's next, how to improve upon ADC, for example, using better drug antibody ratio, talking about new payloads and really new formats that make perhaps ADCs even more potent in the future. There was a session on oral immunotherapeutics. It was really how to target the innate immunity. And I think novel oral immunotherapeutics is very important because we all know PD-1, PD-L1 inhibitors have been the backbone, but we need another Breakthrough. And having oral immunotherapeutics will make it very attractive for patients because they don't have to come to the cancer center to receive the drugs. Another part of that session was about T-cell engagers and bispecifics, really how to bring molecules to the T-cell, to the effective cells so that they are able to be phytotoxic to the tumor. We talked about also oncolytic viruses, how are the new ways to utilize this kind of natural agent to target the cancer cells. And lastly, we also talked about personalized cancer vaccine, which is obviously very timely. We all know a lot about vaccine now after the COVID pandemic and how do we use cancer vaccines to be a good therapeutic drug? I think especially important in the earlier disease stages as adjuvant therapy. Some exciting data, for example, in pancreatic cancer, as adjuvant really is groundbreaking for this whole topic of cancer vaccination. Dr. Melvin Chua: That's great. And for me as a radiation oncologist who's not so deep in drug development, hearing all the talks at ASCO Breakthrough was really informative for me and I learned a lot. In particular, you spoke about the whole session there was oncolytic therapy and the results in glioblastoma multiforme, we know it's a deadly disease, was certainly very impressive. And so, it speaks to the whole notion that in fact, some of this stuff is in fact reaching the clinic and making a difference in deadly diseases. I think there's a lot to take in from there. Dr. Lillian Siu: Melvin, you're so humble. I know you're a big expert in artificial intelligence and I think the whole session about AI applications in precision medicine really was not just in that session, but a whole theme that went throughout the entire meeting. So, I'm very interested to know what you think about some of the presentations around AI and disruptive technologies in precision medicine, such as next-generation multiomics, etc. What are your thoughts? Dr. Melvin Chua: Absolutely, I agree with you. And there was so much material within the AI session, the multiomic session, as well as the keynote [address] by Dr. Maryellen Giger, which basically speaks about some of the pre-existing or historical work on artificial intelligence in radiology. And I'd like to first talk about the keynote by Dr. Maryellen Giger. It was very nice that she elegantly showed how AI was in fact already in practice in radiology, where it helped to fulfill or address a need for radiologists. Almost 20 years ago, they were able to show that using computer vision, you were able to basically facilitate the calling of abnormal mammograms. And it was inspiring to see how these early thoughts have now basically accelerated a lot of the advances that we see that are in practice today. The other thing that was also was to see this global collaboration, the need for global collaboration in the artificial intelligence space and the radiologists are clearly leading the way. And I think part of the impetus for this effort came from an opportunity that arose during the COVID pandemic that clearly affected all facets of healthcare. That was a nice segue to the very sort of dense 1 hour session we had on precision oncology care with artificial intelligence. I think when we designed this session, we were very deliberate that we wanted to address all aspects of how AI could be applied. From real-world clinical data, we saw examples of how having good, well-annotated data sets could actually help to accelerate and facilitate liver cancer screening in Hong Kong. Then we also saw a very simple, practical application of AI in pathology, where apart from just having this tool to be able to extract features that could potentially predict outcomes of patients and predict drug responses, we saw a very practical example that applying AI in digital pathology could actually homogenize or harmonize the ways the pathologists review their cases. And so, I thought that was very neat and could speak to all our clinicians across both developed and developing countries. We also saw very exciting stuff on the use of AI in terms of calling out mutations because we know that next-generation sequencing is pretty much a cornerstone of how we practice in oncology today. And yet we know that there are prohibitive costs that preclude this technology in certain parts of the world. And it was nice to see how AI could actually lower the cost of some of these sequencing technologies like being used in liquid biopsy. And then finally, there was some fancy science as well that was showcased in the spectrum when we saw how industry as well as academics are thinking about integrating multiomic data sets to then be able to accelerate drug discovery, help define patients better, and so that we can think about how to look at precision oncology using targeted treatments for specific patient phenotypes. So I think this was a very nice transition to the Next-Generation Multiomic Technology session, where, again, some of these topics were touched on, ranging from liquid biopsies, and this was already covered in Dr. Abbosh's talk, which you spoke about, and as well as the preceding day session where we heard snippets of it. And it was again reinforced by the speakers when it showcased liquid biopsies. We have heard so much about it in the last decade and we see it made approved now for use in the clinic, but yet so much remains unknown, like the discrepancies between assays, addressing the cost of assays and, importantly, how we deal with the information. So, I think we are just at the tip of the iceberg here. A lot of the clinical evidence needs to be generated in due course to address some of these questions. At the same time, it was also nice to see some of the new technologies being applied in discovery science. So, we know that immunotherapy is a major player in oncology today, and the Breakthrough represents a forum whereby we're able to bring translational scientists to showcase their work. And we saw examples of that at this meeting where single cell technology, digital spatial technology, being able to apply that in pathology specimens and how the two are integrated to be able to review more novel science to us, to show us how immunotherapy works or doesn't work in some patients. Both of us have touched on so much content that was showcased at the Breakthrough, and I think this speaks to the impact, the learning experience we've had from Breakthrough and I think that's the intended purpose of this meeting. Dr. Lillian Siu: Yeah, I agree. It truly was a very exciting 3 days. And I particularly like the multiomics session where we see that the technology is so advanced just in a really short period of time. Over the last few years, we've been now able to go into single cell resolution where in the past I don't think we would ever dream of being able to do that. In fact, I recall in the single cell session, we can even see messenger RNA on the slide, which I thought was fascinating, something that I cannot imagine we can see by the naked eye. It really is an exciting time in oncology, Melvin, and the field is advancing with these new innovations and therapies, but at the same time, I think it's important that we do live globally and we need to work really also to help improve access to quality-assured cancer medicines and diagnostics in the low and middle income countries. What do you think about that part? Did we do a good job in addressing that in the meeting? Dr. Melvin Chua: Absolutely, Lillian. We had a special session that was chaired by Dr. Peter Yu and the lecture was delivered by Dr. Gilberto Lopes from the University of Miami. And we know that he's a strong advocate for this. And the session title spoke to this topic very pointedly, “How Science, Technology, and Practice Can Be Enabled in Lower- and Middle-Resource Settings.” And I thought that the work that he highlighted, the whole ATOM coalition, was important. ATOM basically stands for Access to Oncology Medicines, and it was established last year by the UICC, the Union for International Cancer Control, along with global partners to improve access to anti-cancer drugs and to develop processes for ensuring quality delivery, as well as the optimal utilization of medicines in middle- and low-resource settings. And I think there's a lot more work to be done. Some of the information they showed was very compelling to me from this part of the world. But we know that Asia isn't very heterogeneous in terms of the resources, in terms of the culture. And I thought that the drug pricing, for example, how that should be addressed across the different countries is an important topic to pick up. And I hope his lecture only invigorates this conversation going forward. Dr. Lillian Siu: Yeah. Thanks, Melvin. I totally agree. That was very inspiring. Breakthrough is such a one of a kind, international gathering that we are not only able to network while we're there; we also have a session to really allow attendees to leverage international cancer networks, to learn a bit about them, all the way from, for example, some of the North American groups to Asia Pacific groups to even global groups, and how we interact between pharma and academia, really transcending boundaries. And I think it is really, really important for us to now have these networks address issues such as equity and cancer care innovation, novel approaches and so much more. And I think, I am sure you're going to do a good job in making sure that gets into the agenda in our next year's meeting in 2024. Ultimately, we hope that these collaborations in cancer research will help to improve the outcomes for our patients with cancer. Dr. Melvin Chua: Thank you again for sharing the great highlights of ASCO Breakthrough, and I'm really appreciative of your work, and your commitment to build a really robust program for this year. So, thank you. Dr. Lillian Siu: And thank you, Dr. Chua. And you can bet that I will not miss Breakthrough 2024 in Yokohama in August next year. I will be there. Dr. Melvin Chua: Okay, I'll hold you to that. And thank you to our listeners for your time today. You'll find links to all of the sessions discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Lilian Siu @lillian_siu Dr. Melvin Chua @DrMLChua Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Lillian Siu: Leadership (Immediate family member): Treadwell Therapeutics Stock and Other Ownership Interests (Immediate family member): Agios Consulting or Advisory Role: Merck, AstraZeneca/MedImmune, Roche, Voronoi Inc., Oncorus, GSK, Seattle Genetics, Arvinas, Navire, Janpix, Relay Therapeutics, Daiichi Sankyo/UCB Japan, Janssen, Research Funding (Institution): Bristol-Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, Astellas Pharma, Shattuck Labs, Symphogen, Avid, Mirati Therapeutics, Karyopharm Therapeutics, Amgen Dr. Melvin Chua: Leadership, Stock and Other Ownership Interests: Digital Life Line Honoraria: Janssen Oncology, Varian Consulting or Advisory Role: Janssen Oncology, Merck Sharp & Dohme, ImmunoSCAPE, Telix Pharmaceuticals, IQVIA, BeiGene Speakers' Bureau: AstraZeneca, Bayer, Pfizer, Janssen Research Funding: PVmed, Decipher Biosciences, EVYD Technology, MVision, BeiGene, EVYD Technology, MVision, BeiGene Patents, Royalties, Other Intellectual Property: High Sensitivity Lateral Flow Immunoassay for Detection of Analyte in Samples (10202107837T), Singapore. (Danny Jian Hang Tng, Chua Lee Kiang Melvin, Zhang Yong, Jenny Low, Ooi Eng Eong, Soo Khee Chee)
Episode 73. Julio de Unamuno IV is the Founder & CEO of LabFellows and Executive Director of HomeLab, the biotech accelerator at UC San Diego's Center for Novel Therapeutics. He did his undergrad in Biochemistry at the University of San Diego and an MBA at the UC San Diego, Rady School of Management.
CME credits: 0.50 Valid until: 21-07-2024 Claim your CME credit at https://reachmd.com/programs/cme/novel-therapeutics-treating-the-adverse-events-from-ssri-and-snri-monotherapy/15802/ Many patients with Major Depressive Disorder (MDD) do not adequately respond to or fail first-line antidepressant therapy causing significant setbacks in patient care and dramatic decreases in QoL. The lack of agreement on approaching the next treatment step creates a significant gap, leading to suboptimally treated MDD. Clinicians have the option to augment therapy or switch to another class of antidepressants to improve the management of a patient's residual symptoms of MDD. This program will help highlight the appropriate treatment for individuals with MDD who are suboptimally treated and provide evidence-based best practices related to making a timely switch from a first-line to a second-line antidepressant or augmenting the current treatment option.
Dr Barnes reviews key abstracts from ECCO 2023 on novel therapeutics for inflammatory bowel disease with hosts Drs Raymond Cross and Millie Long.
This week, we present reports on four important presentations made during the American Association for Cancer Research (AACR) Annual Meeting, focusing on novel inhibitory therapeutics; adjuvant immunotherapy for patients with hepatocellular carcinoma at high risk of recurrence; the effect of treatment protocols guided by precision medicine on survival for patients with relapsed or refractory cancer; and community engagement for clinical trial recruitment. To listen to more podcasts from ASCO, visit asco.org/podcasts.
Alex A. Adjei, MD, PhD, Chair of Cleveland Clinic Taussig Cancer Institute, joins the Cancer Advances podcast to discuss the new Novel Therapeutics Clinic. Listen as Dr. Adjei shares the importance of novel cancer therapetuics, how the clinic is structured, and his hopes of having multiple treatment options for every cancer.
To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/igan-ee-podcastThis activity will take learners on a deep dive into the pathophysiology of proteinuric glomerular disease, with an incisive focus on IgA nephropathy (IgAN). Expert faculty will review the totality of emerging evidence for novel therapeutics in IgAN, including an appraisal of consensus guidelines and regulatory updates. Finally, the session will conclude with a case-based segment wherein attendees will get to apply the principles they've learned to real-world clinical scenarios.Supported through an independent educational grant from Travere.
In this episode, Anusha guides you through 11 papers that were published in November of 2022. These papers study the efficacy of treatments targeting neuroprotection in Alzheimer's Disease models. Tune in if you want to be on the cutting edge of drug discovery and development in the field of AD. Sections in this episode: Drug Discovery and Development of Novel Therapeutics (3:49) Testing Existing Compounds (17:27) -------------------------------------------------------------- To find the numbered bibliography with all the papers covered in this episode, click here, or use the link below:https://drive.google.com/file/d/1osewDiGUB7cy55VgU6YdG2f4dyqR4mvT/view?usp=share_linkTo access the folder with ALL our bibliographies, follow this link (it will be updated as we publish episodes and process bibliographies), or use the link below:https://drive.google.com/drive/folders/1bzSzkY9ZHzzY8Xhzt0HZfZhRG1Gq_Si-?usp=sharingYou can also find all of our bibliographies on our website: amindr.com. --------------------------------------------------------------Follow-up on social media for more updates!Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastFacebook: AMiNDR Youtube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com -------------------------------------------------------------- Please help us spread the word about AMiNDR to your friends, colleagues, and networks! And if you could leave us a rating and/or review on your streaming app of choice (Apple Podcasts, Spotify, or wherever you listen to the podcast), that would be greatly appreciated! It helps us a lot and we thank you in advance for leaving a review! Don't forget to subscribe to hear about new episodes as they come out too. Thank you to our sponsor, the Canadian Consortium of Neurodegeneration in Aging, or CCNA, for their financial support of this podcast. This helps us to stay on the air and bring you high quality episodes. You can find out more about the CCNA on their website: https://ccna-ccnv.ca/. Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted, hosted and edited by Anusha Kamesh, and reviewed by Naila Kuhlmann. The bibliography and wordcloud were created by Lara Onbasi (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For November 2022, the sorters were Sarah Louadi, Eden Dubchak, Ben Cornish, Christy Yu, Dana Clausen, Kevin Nishimura, Anelya Gandy, Salodin Al-Achkar, Ellen Koch, and Elyn Rowe. Also, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Lara Onbasi, Joseph Liang, and Judy Cheng, for keeping everything running smoothly.Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic. https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways. --------------------------------------------------------------*About AMiNDR: * Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!"
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Paolo Ventura, MD - Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Join Drs Cohen and Gibofsky as they step through a case of refractory psoriatic arthritis, discuss novel therapeutics, review latest clinical trials, and talk about the future in psoriatic arthritis. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/970786). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals. Resources Psoriatic Arthritis Workup https://emedicine.medscape.com/article/2196539-workup#c6 GRAPPA Treatment Recommendations: 2021 Update https://www.jrheum.org/content/49/6_Suppl_1/52.long Methotrexate in Psoriasis and Psoriatic Arthritis https://www.jrheum.org/content/96/31 Psoriatic Arthritis Medication https://emedicine.medscape.com/article/2196539-medication#4 Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients https://www.jrheum.org/content/47/6/854 Three JAK Inhibitors Get Boxed Warnings, Modified Indications https://www.medscape.com/viewarticle/958024 Effect of Tofacitinib on Patient-Reported Outcomes in Patients With Active Psoriatic Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors in the Phase III, Randomised Controlled Trial: OPAL Beyond https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340607/ Upadacitinib in Patients With Psoriatic Arthritis and an Inadequate Response to Non-biological Therapy: 56-Week Data From the Phase 3 SELECT-PsA 1 Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524381/ Multicentre, Randomised, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Naïve to Biological Disease-Modifying Antirheumatic Drug: Final Results by Week 52 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509529/ Improvement in Patient-Reported Outcomes in Patients With Psoriatic Arthritis Treated With Upadacitinib Versus Placebo or Adalimumab: Results From SELECT-PsA 1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572257/ Bimekizumab in Patients With Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(19)33161-7 A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment https://clinicaltrials.gov/ct2/show/NCT04908189
In this episode of the Ownership Economy, we speak with Molecule Protocol's Co-Founder and Chief Scientific Officer Tyler Golato. Molecule is creating collaborative ecosystems, where stakeholders in drug development can work together to expedite the process of bringing novel therapeutics to patients. The company is connecting leading researchers to funding by turning intellectual property and its development into a liquid and easily investable asset. We talk with Tyler about the model, how the company isapproaching progressive decentralization, and where algorithmic rules of governance intersect with the need for human decision making. We hope you enjoy the episode.
The Real Truth About Health Free 17 Day Live Online Conference Podcast
New 2022 - Cancer As A Metabolic Disease: Implications For Novel Therapeutics - Thomas N. Seyfried, PhD Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism. However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited. This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention. Support for this position is derived from critical assessment of current cancer theories. Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate.The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).”To Contact Dr Thomas N. Seyfried, Ph.D. email: thomas.seyfried@bc.edu CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth • Check out our Podcasts Visit us on Apple Podcast and Itunes search: The Real Truth About Health Free 17 Day Live Online Conference Podcast Amazon: https://music.amazon.com/podcasts/23a037be-99dd-4099-b9e0-1cad50774b5a/real-truth-about-health-live-online-conference-podcastSpotify: https://open.spotify.com/show/0RZbS2BafJIEzHYyThm83J Google:https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS8yM0ZqRWNTMg%3D%3DStitcher: https://www.stitcher.com/podcast/real-truth-about-health-live-online-conference-podcastAudacy: https://go.audacy.com/partner-podcast-listen-real-truth-about-health-live-online-conference-podcastiHeartRadio: https://www.iheart.com/podcast/269-real-truth-about-health-li-85932821/ Deezer: https://www.deezer.com/us/show/2867272 Reason: https://reason.fm/podcast/real-truth-about-health-live-online-conference-podcast • Other Video ChannelsYoutube:https://www.youtube.com/c/TheRealTruthAboutHealthVimeo:https://vimeo.com/channels/1733189Rumble: https://rumble.com/c/c-1111513 Facebook:https://www.facebook.com/TRTAHConference/videos/?ref=page_internal DailyMotion: https://www.dailymotion.com/TheRealTruthAboutHealth BitChute: https://www.bitchute.com/channel/JQryXTPDOMih/ Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims.
Did you know that there are oral and nonoral treatments for migraine, along with non-pharmacologic options? Join our expert faculty to learn more. Credit available for this activity expires: 10/12/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982182?src=mkm_podcast_addon_982182
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective and safe way—and lead to improved outcomes in MF? Based on a recent PeerView Live CaseBook event, this activity will answer that question and offer an expert-led review of the latest efficacy, safety, and tolerability data associated with JAKi-based therapy and the role of HCT in patient treatment. This program also features case-based illustrations of therapy selection and sequencing designed to highlight the key take-homes of the MF lecture segments. Upon completion of this activity, participants should be better able to: Assess patient- and disease-related features that inform the diagnosis, risk assessment, and treatment of myelofibrosis (MF), Analyze the current therapeutic roles of JAK inhibitors and other emerging therapies in the peri-transplant setting for managing patients with MF, Apply current data on the safety, efficacy, and tolerability of JAK inhibitors and other emerging therapeutic options for treating transplant-eligible patients with MF, Develop treatment plans that incorporate first- and second-generation JAK inhibitors for managing patients with MF, including those who are eligible for allogeneic HSCT or as sequential options in the non-HSCT setting.
In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studiesHBV cure from the Everest Project in ChinaHDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertensionHCV retreatment in patients with prior direct-acting antiviral therapy failurePresenter: Stefan Zeuzem, MDProfessor of MedicineChief, Department of Medicine I JW Goethe University Hospital Frankfurt, GermanyFollow along with the downloadable slideset at:https://bit.ly/3yJAruDLink to full program: https://bit.ly/3AjCNBC
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient's baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruction on how to integrate novel targeted, HMA, and antibody-based options into the management of HCT-eligible AML. Throughout, they provide insights on how to choose appropriate induction, conditioning, post-remission, and maintenance options, as well as discuss treatment plans for relapsed/refractory disease. Watch this program to see how novel therapeutics are changing paradigms and challenging long-standing practices in the management of HCT-eligible AML. Upon completion of this activity, participants should be better able to: Identify baseline clinical and molecular factors that can inform prognosis and treatment decisions for transplant-eligible patients with acute myeloid leukemia (AML), Employ modern therapeutics as components of personalized induction, consolidation, and maintenance/post-remission regimens for transplant-eligible patients with AML in accordance with updated safety and efficacy evidence and current guidelines, Integrate novel therapeutics into the management of patients with relapsed/refractory (R/R) AML, including as pre-transplant conditioning or as salvage options post-HCT.
In this episode, Nancy Reau, MD, discusses new viral hepatitis data from EASL 2022, including:Novel therapeutics for HBVTherapeutic vaccination for HBVEmerging treatment options for HDVHCV care cascadeHCC monitoring after HCV curePresenter: Nancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisFollow along with the downloadable slideset at: https://bit.ly/3yJAruDLink to full program:https://bit.ly/3IeUapm
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics
This activity will review how social determinants of health have led to inequities and disparate outcomes in HF. Attendees will take part in an expert-led exploration of current treatment guidelines, with an emphasis on HFrEF, and a review of emerging novel therapeutics. Learners will review real-world cases, empowering them to effectively interpolate novel agents into established guideline-directed medical therapy (GDMT) protocols and promote the closure of outcomes chasms driven by disparities in care.Supported by an independent educational grant from Merck.
Elaine Husni, MD, MPH, and Ana-Maria Orbai, MD, MHS, discuss the emerging and novel therapeutics in psoriatic arthritis and the impact that they will have on their patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/viewarticle/959157). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis https://www.rheumatology.org/Portals/0/Files/PsA-Guideline-2018.pdf EULAR Recommendations for the Management of Psoriatic Arthritis With Pharmacological Therapies: 2019 Update https://ard.bmj.com/content/79/6/700.1 Treatment Guidelines in Psoriatic Arthritis https://academic.oup.com/rheumatology/article/59/Supplement_1/i37/5802853 Bimekizumab in Patients with Active Psoriatic Arthritis: Results From a 48-Week, Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)33161-7/fulltext
On this week's podcast, we have three conversations: with Ian Smith, sales director at PFF; Dr Ardythe Morrow, Professor of Epidemiology and Pediatrics at the University of Cincinnati College of Medicine and Cincinnati Children's Hospital Medical Center; and Wopke Beukema, senior manager R&D at PerkinElmer, Inc.
Did you know that hearing loss is one of the largest areas of unmet need in medicine? It affects approximately 466 million people worldwide, including 48 million people in the United States. Today's guest Laurence Reid, CEO of Decibel Therapeutics dives deeper into meeting that unmet need. Decibel has architected a whole platform to restore hearing and balance loss. With several treatments in their pipeline now, one in phase 1 clinical trials, they're making great progress. Learn more about how Decibel started, current pipeline, and the future of biotech industry. About Laurence Reid, Ph.D.Laurence joined Decibel in January 2020. He previously served as an entrepreneur in residence at Third Rock Ventures, where he focused on novel drug discovery and development opportunities. Before that, Laurence was CEO of Warp Drive Bio, a small molecule company focused on novel oncology and antibiotic drug discovery based on natural products, until its merger with Revolution Medicines in 2018. Prior to that, he was the senior vice president and chief business officer of Alnylam Pharmaceuticals, where he was responsible for the company's business development, finance and legal functions. Before coming to Alnylam, Laurence was the chief business officer at Ensemble Discovery, where he led the company's strategic planning and corporate development efforts. Laurence previously spent ten years at Millennium Pharmaceuticals in a range of general management and business development positions. In addition to his professional interests, Laurence is a board member of the Possible Project, a board member of Garuda Therapeutics and board advisor to Life Science Cares. He earned his Ph.D. from King's College London and his B.A. from Cambridge University.About DecibelDespite the overwhelming burden of hearing loss and balance disorders, the search for therapeutics to treat these conditions remains one of the largest areas of unmet needs in medicine. At Decibel, we are exclusively focused on discovering and developing transformative treatments to restore and improve hearing and balance. We have assembled a highly experienced scientific team and built a unique platform to achieve this goal.Show notesDecibel website: https://decibeltx.com/Pictures of the inner ear: https://www.decibeltx.com/our-approach/QualioPrevious episodes: https://www.qualio.com/from-lab-to-launch-podcastApply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8Music by keldez
Join Kate for a comprehensive summary of everything tau from papers published in November 2021. We'll talk post-translational modifications, prion-like seeding pathology, molecular modeling, and even touch on a potential AD therapies targeting this fascinating little microtubule helper. Enjoy! :) Sections in this episode: Tau Aggregation and Post-Translational Modifications (03:03) Tau Seeding and General Tau Pathology (12:49) Novel Therapeutics (22:58) -------------------------------------------------------------- To find the numbered bibliography with all the papers covered in this episode, click here, or use the link below:https://drive.google.com/file/d/1bN5cizXqwbfTb-zaQsSckYjMcyz75kzF/view?usp=sharingTo access the folder with all the bibliographies for 2021 papers, follow this link (it will be updated as we publish episodes and process bibliographies), or click the following link below:https://drive.google.com/drive/folders/1N1zx_itPkCDNYE1yFGZzQxDDR-NiRx3p?usp=sharingYou can also find all of our bibliographies on our website: www.amindr.com. --------------------------------------------------------------Follow-up on social media for more updates!Facebook: AMiNDR Twitter: @AMiNDR_podcastInstagram: @AMiNDR.podcastYoutube: AMiNDR PodcastLinkedIn: AMiNDR PodcastEmail: amindrpodcast@gmail.com -------------------------------------------------------------- Please help us by spreading the word about AMiNDR to your friends, colleagues, and networks! Another way you can help us reach more listeners who would benefit from the show is by rating and/or reviewing us on Apple Podcasts, Spotify, or wherever you listen to podcasts. It helps us a lot and we thank you in advance for leaving a review! Our team of volunteers works tirelessly each month to bring you every episode of AMiNDR. This episode was scripted and hosted by Kate Van Pelt, edited by Lara Onbasi, and reviewed by Alyssa Ash and Anusha Kamesh. The bibliography was made by Anjana Rajendran, and the wordcloud was created by Sarah Louadi (www.wordart.com). Big thanks to the sorting team for taking on the enormous task of sorting all of the Alzheimer's Disease papers into episodes each month. For November 2021, the sorters were Jacques Ferreira, Christy Yu, Kate Van Pelt, Kira Tosefsky, Dana Clausen, Nicole Corso, Eden Dubchak, Ben Cornish, Ellen Koch, Elyn Rowe, and Naila KuhlmannAlso, props to our management team, which includes Sarah Louadi, Ellen Koch, Naila Kuhlmann, Elyn Rowe, Anusha Kamesh, Jacques Ferreira for keeping everything running smoothly.Our music is from "Journey of a Neurotransmitter" by musician and fellow neuroscientist Anusha Kamesh; you can find the original piece and her other music on soundcloud under Anusha Kamesh or on her YouTube channel, AKMusic. https://www.youtube.com/channel/UCMH7chrAdtCUZuGia16FR4w -------------------------------------------------------------- If you are interested in joining the team, send us your CV by email. We are specifically looking for help with sorting abstracts by topic, abstract summaries and hosting, audio editing, creating bibliographies, and outreach/marketing. However, if you are interested in helping in other ways, don't hesitate to apply anyways. --------------------------------------------------------------*About AMiNDR: * Learn more about this project and the team behind it by listening to our first episode: "Welcome to AMiNDR!"
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/VVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in graft-versus-host disease (GVHD) provide learners with a solid grounding in the underlying biology and immunologic rationale for the use of various treatment modalities throughout the GVHD spectrum, including steroid-naïve and steroid-refractory disease, while also detailing how the clinical evidence to date on novel agents should inform the prevention and treatment of this disease in hematopoietic stem cell transplant recipients. Upon completion of this activity, participants should be better able to: Describe the pathogenesis of post-HCT GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD; Summarize current data surrounding innovative therapies for the prevention or treatment of acute or chronic, steroid-naïve or steroid-refractory GVHD in the HCT setting; Integrate approved and emerging therapies into treatment plans, including clinical trial enrollment, for post-HCT GVHD care based on individual patient and disease characteristics.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
Go online to PeerView.com/TYB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the emergence of immunotherapy as an essential component in the treatment armamentarium for bladder cancer, the therapeutic landscape for this disease has undergone significant transformation in recent years. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. These experts review the latest data and ongoing research on immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics. Upon completion of this activity, participants will be able to: Review the rationale for use of and latest evidence with approved and investigational therapies, including immune checkpoint inhibitors, antibody–drug conjugates, and FGFR inhibitors, throughout the bladder cancer disease continuum, Describe the role of available and emerging biomarkers in personalizing therapy with immune checkpoint inhibitors and other novel strategies for patients with bladder cancer, Employ new and emerging treatment approaches optimally for the management of bladder cancer, with considerations of the benefits and risks of therapy, patient and disease characteristics, and patient needs and preferences, Incorporate patient-centric strategies to identify and manage treatment-emergent adverse reactions associated with new regimens for bladder cancer, Recommend current and ongoing clinical trials incorporating checkpoint blockade and novel targeted approaches to eligible patients across disease settings in bladder cancer.
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Go online to PeerView.com/CQB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity based on a recent live symposium preceding the 61st ASH Annual Meeting and Exposition, experts in non-Hodgkin lymphoma present a series of “tumor board”–style case discussions and scientific lectures focused on key issues in the selection and use of newer therapeutics—including BTK, PI3K, and BCL-2 inhibitors; IMiDs; antibodies; and CAR T therapy—in different NHL histologies. The panel also presents clinically meaningful evidence that supports the decisions discussed during the tumor board sessions and profiles new developments related to the use of innovative therapeutics in diseases such as follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Upon completion of this activity, participants should be better able to: Cite efficacy and safety evidence surrounding novel therapeutic classes, including B-cell receptor inhibitors, antibodies, BCL-2 inhibitors, IMiDs, and CAR T cell therapy, in the B-cell lymphoma setting, Integrate novel agent classes into treatment plans for newly diagnosed or relapsed/refractory B-cell cancers, such as FL, MCL, and DLBCL, while considering baseline risk factors and patient characteristics, Manage the unique spectrum of adverse events associated with the use of newer therapeutics in the B-cell cancer setting
Video PodcastAired date: 3/23/2011 3:00:00 PM Eastern Time
Enhanced Video Podcast- Part 2Aired date: 12/7/2006 8:00:00 AM Eastern Time
Enhanced Video Podcast- Part 1Aired date: 12/7/2006 8:00:00 AM Eastern Time
Enhanced Video PodcastAired date: 12/8/2006 8:00:00 AM Eastern Time